Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

Oxygen Biotherapeutics Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attack and strokes. Oxycyte is the company’s perfluorocarbon (PFC) therapeutic oxygen carrier.

The company’s invention, called Vitavent, provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be used easily by a victim of a heart attack or stroke, who is still conscious, without the assistance of another. It also may be used by someone who cannot adequately perform CPR in order to assist someone who is unconscious.

By safely combining Oxycyte and oxygen, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim’s lung an oxygen load that is 50 times greater than